Going further for childhood cancer
We’re setting our sights on creating more effective, targeted medicines for children and young people with cancer, bridging the gap between the lab and patients.
Children's Cancer Therapeutics Consortium
Core partners
C-Further unveils first therapeutic programmes dedicated to paediatric oncology
10 March 2026
C‑Further launches its first targeted paediatric cancer programmes, collaborating with global academic and industry partners to advance new therapeutics for Ewing sarcoma, bone sarcoma, medulloblastoma and childhood AML.
How we can help
Rising to the challenge of cancers affecting children and young people will require a fundamental change in the way cancer drugs for this group are discovered, developed and brought to market. That's why we're providing funding and drug discovery lab support to de-risk early stage therapeutic projects and increase their chances of being picked up by industry and impact investors.
We’ve reached a critical milestone of £37M (USD $50M) committed in resource and funding, which we're using to drive change through collaborative research, partnerships and funding. Join our mission and work with us to help make a difference for children and young people with cancer.
Industry-leading expertise
Bringing together leading experts in research, translational science, drug discovery and development.
Extensive resources
Offering access to world-class drug discovery and development laboratories to accelerate and de-risk promising research.
Transformational models
Raising and managing the financing needed to progress research aimed at developing new treatments for children and young people affected by cancer.
Dynamic collaboration
Convening international experts and complementary skillsets – bringing like-minded organisations and people together to provide resources and expertise to propel innovations along the drug development pathway.
About us: our core partners
Cancer Research Horizons
Cancer Research Horizons is the innovation engine of Cancer Research UK – the world's largest charitable funder of cancer research. It takes cutting-edge innovations from the lab to the patient, translating them into effective treatments and diagnostics.
LifeArc
LifeArc is a self-funded, not-for-profit medical research organisation and charity. LifeArc provides funding, research and expert knowledge to help take science ideas out of the lab and turn them into life-changing medical breakthroughs for patients.
Great Ormond Street Hospital (GOSH Charity)
GOSH Charity is the largest charitable funder of medical research dedicated to child health in the UK. Alongside this, it provides funding to Great Ormond Street Hospital for cutting-edge medical equipment, facilities and life-changing support.
C-Further will bring together the brightest minds in cancer research to bolster translation of discovery research, drive clinical progress and meaningfully improve the lives of children and young people with cancer.
Iain Foulkes
CEO, Cancer Research Horizons | Executive Director of Research and Innovation, Cancer Research UK
For researchers
Do you have a validated target or an early-stage therapeutic asset with potential in a cancer affecting children and young people?
For partners
Do you share our vision for transformative treatments specifically targeting the drivers of childhood cancers?
Rising to the challenge of childhood cancer requires a fundamental change in the way children’s and young people’s cancer drugs are discovered, developed and brought to market. C-Further is committed to driving that change.
David Jenkinson
Head of Childhood Cancer Translational Challenge, LifeArc
News and events
We are creating a consortium united in the unwavering belief that we can challenge conventional approaches and accelerate translation of promising ideas into new therapies for children and young people affected by cancer.
Stay up to date on our latest news, events and research.
A little hero's journey: our duty to deliver
John Rainsbury on his son Will's cancer journey and the hope that new paediatric research might bring to children affected by cancer and their families.
C-Further unveils first therapeutic programmes dedicated to paediatric oncology
C‑Further launches its first targeted paediatric cancer programmes, collaborating with global academic and industry partners to advance new therapeutics for Ewing sarcoma, bone sarcoma, medulloblastoma and childhood AML.
From Chemo to CAR-T: A mum’s call for Child-First Drug Design
Courtney Addison on her son Cayden's cancer journey and the need for more targeted paediatric cancer treatments in an interview with C-Further.
Podcast: Changing the Playbook on Childhood Cancers
In this episode of RAREcast, Daniel Levine, a leading voice in oncology innovation, speaks with David Jenkinson of LifeArc about C-Further and what makes it a standout model in the current paediatric cancer translational science landscape.